C07D279/02

Organic molecules for use in optoelectronic devices
10263196 · 2019-04-16 · ·

The invention relates to an organic molecule having precisely two units of formula I linked to one another via a single bond or a bridge Y ##STR00001## where Y=a divalent group; X=at each occurrence identically or differently CN and CF.sub.3; D=chemical unit having a structure of the formula I-1: ##STR00002## where #=attachment point of the unit of formula I-1 to the structure of formula I; A and B=independently of one another are selected from the group consisting of CRR.sup.1, CR, NR, N, there being a single or double bond between A and B and a single or double bond between B and Z; Z=a direct bond or a divalent organic bridge which is a substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group or a combination thereof, CRR.sup.1, CCRR.sup.1, CNR, NR, O, SiRR.sup.1, S, S(O), S(O).sub.2, O-interrupted substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group, phenyl units or substituted phenyl units.

Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer

The present invention provides MDM2 inhibitor compounds of Formula I,

##STR00001## wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer

The present invention provides MDM2 inhibitor compounds of Formula I,

##STR00001## wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway

The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases.

Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway

The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases.

HIV REPLICATION INHIBITOR

The present invention provides a novel compound having an antiviral activity, in particular, an HIV replication inhibiting activity, as well as a pharmaceutical composition, in particular, an anti-HIV agent.

##STR00001##

wherein ring A is substituted or unsubstituted carbocycle or substituted or unsubstituted heterocycle; R.sup.1 is substituted or unsubstituted alkyl etc.; R.sup.2 is substituted or unsubstituted alkyloxy etc.; n is 1 or 2; R.sup.3 is substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl; R.sup.4 is a hydrogen atom etc.; R.sup.6 is substituted or unsubstituted alkyl etc.

HIV REPLICATION INHIBITOR

The present invention provides a novel compound having an antiviral activity, in particular, an HIV replication inhibiting activity, as well as a pharmaceutical composition, in particular, an anti-HIV agent.

##STR00001##

wherein ring A is substituted or unsubstituted carbocycle or substituted or unsubstituted heterocycle; R.sup.1 is substituted or unsubstituted alkyl etc.; R.sup.2 is substituted or unsubstituted alkyloxy etc.; n is 1 or 2; R.sup.3 is substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl; R.sup.4 is a hydrogen atom etc.; R.sup.6 is substituted or unsubstituted alkyl etc.

Aryl sultam derivatives as RORc modulators

Compounds of the formula I: ##STR00001##
or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X.sup.1, X.sup.2, X.sup.3, X.sup.4, Y, Z, A, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12 and R.sup.13 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.

Aryl sultam derivatives as RORc modulators

Compounds of the formula I: ##STR00001##
or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X.sup.1, X.sup.2, X.sup.3, X.sup.4, Y, Z, A, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12 and R.sup.13 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.

POLYAMINE SULFONAMIDES AND USES THEREOF

Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds with antineoplastic activity. Provided herein are polyamine sulfonamides such as compounds of Formula (I), or pharmaceutically acceptable salts thereof, which may be used in the treatment and/or prevention of diseases such as cancer. Also provided herein are pharmaceutical compositions and kits comprising the inventive compounds. Furthermore, the present invention provides methods of treating and/or preventing diseases (e.g., cancer) using compounds of Formula (I), or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof. Other methods provided include methods for inducing apoptosis of a cell, as well as methods for inhibiting alpha-enolase enzymatic activity in vivo and in vitro.